Nutritional and Metabolic Issues in Solid Organ Transplantation: Targets for Future Research

Journal of Renal Nutrition

Volumn 19, Issue 1, 2009, Pages 111-122

  Ward, Harry J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; METABOLIC SYNDROME X; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METABOLIC SYNDROME X; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 58049188826     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2008.10.020     Document Type: Article

References (95)

1. Terasaki P.I. Clinical Transplants (2006) Terasaki Foundation Laboratory
2. Ojo A.O. Cardiovascular complications after renal transplantation and their prevention. Transplantation 82 (2006) 603-611
3. Yamani M.H., and Starling R.C. Long term medical complications of heart transplants: information for primary care providers. Cleveland Clinic J Med 67 (2000) 673-680
4. Futagawa Y., Terasaki P.I., Waki K., et al. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transplant 6 (2006) 1398-1408
5. Satyan S. RocherLL: Impact of kidney transplantation on the progression of cardiovascular disease. Adv Chronic Kidney Dis 11 (2004) 274-293
6. Vanrenterghan Y.Y., Claes K., Montaenino G., et al. Risk factors for cardiovascular events after successful heart transplantation. Transplantation 85 (2008) 209-216
7. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1555-1607
8. Executive summary of the third report of the National Cholesterol Education Program Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol In Adults (panel III JAMA 285 (2001) 2486-2497
9. Vega G.L. Obesity, the metabolic syndrome and cardiovascular disease. Am Heart J 142 (2001) 1108
10. Frohlich J., Dobiasova M., Lear S., et al. The role of risk factors in the development of atherosclerosis. Crit Rev Clin Lab Sci 38 (2001) 401-440
11. Dulcoux D., Kazory A., Simula-Faivre D., et al. One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant 5 (2005) 2922-2928
12. Valentine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 23 5 Suppl (2004) S187-S193
13. Kalanter-Zadeh K. Causes and consequences of the reverse epidemiology of body mass index in dialysis patients. J Ren Nutr 15 (2005) 142-147
14. Armstrong K.A., Campbell S.B., Hawkey C.M., et al. Obesity is associated with worsening cardiovascular risk profiles and proteinuria progression in renal transplant recipients. Am J Transplant 5 (2005) 2710-2718
15. de Mattos A.M., Prather J., Olyaei A.J., et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int 70 (2006) 757-764
16. Kobashigawa J.A., Starling R.C., Mehra M.R., et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Tranplant 25 (2006) 1063-1069
17. Gore J.L., Pham P.T., Danovitch G.M., et al. Obesity and outcome following renal transplantation. Am J Transplant 6 (2006) 357-363
18. Meier-Kriesche H.U., Vaghela M., Thambuganipalle R., et al. The effect of body mass index on long-term renal allograft survival. Transplantation 68 (1999) 1294-1297
19. Patel R., and Paya C. Infections in solid-organ transplant recipients. Clin Microbiol Rev 10 (1997) 86-96
20. Schold J.D., Srinivas T.R., Guerra G., et al. A 'weight-listing' paradox for candidates of renal transplantation?. Am J Transplant 7 (2007) 550-559
21. el Agroudy A.E., Wafa E.W., Oe G., et al. Weight gain after renal transplantation is a risk factor for patient and graft outcome. Transplantation 77 (2004) 1381-1385
22. Thoma B., Grover V.K., and Shoker A. Prevalence of weight gain in patients with better renal transplant function. Clin Nephrol 65 (2006) 408-414
23. Johansson A.C., Waarda M., Johannson E., et al. Body composition studies in patients accepted for renal transplantation. Am J Renal Nutr 18 Suppl 1 (2008) S22
24. Rike A.H., Mogilisthetty G., Alloway V., et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplants: comparison of early steroid withdrawal and chronic steroids. Clin Tranplant 22 (2008) 229-235
25. El Haggan W., Vendrely B., Chauveau P., et al. Early evolution of nutritional status and body composition after kidney transplantation. Am J Kidney Des 40 (2002) 629-637
26. Dreschsler C., Krane V., Winkler K., et al. Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis. J Renal Nutr S16 (2008)
27. Huang J.W., Yen C.J., Chiang H.W., et al. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 43 (2004) 1047-1055
28. Chudek J., Adamczak M., Karkoszka H., et al. Plasma adiponectine levels before and after successful kidney transplantation. Transplant Proc 35 (2003) 2186-2189
29. Adamczak M., Szotowska M., Chudak J., et al. Plasma adiponectin concentration in patients after successful kidney transplantation: a single center observational study. Clin Nephrol 67 (2007) 381-390
30. Kagan A., Haran N., Leschinsky L., et al. Serum concentrations of leptin in heart, liver and kidney transplant recipients. Isr Med Assoc J 4 (2002) 213-217
31. van Ree R.M., de Vries A.P., Oterdoom L.H., et al. Abdominal obesity and smoking are important determinants of C-reactive protein in renal transplant patients. Nephrol Dial Transplant 20 (2005) 2524-2531
32. Cano N.J., Richard C., Roth H., et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 126 (2004) 540-546
33. Teplan V., Schevch O., Racek J., et al. Assymmetric dimethylarginine and adiponectin after renal transplantation: role of obesity. J Renal Nutr 18 (2008) 154-157
34. Winkelmayer W.C., Kramar R., Curhan G.C., et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol 16 (2005) 255-260
35. Dulcoux D., Motte G., Challier B., et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 11 (2000) 149-151
36. Ward H.J. Commentary: Uric acid as a risk factor for hypertension. Lancet 352 (1998) 670-671
37. Siirtola A., Antikainen M., Ala-Houhala M., et al. Serum lipids in children 3 to 5 years after kidney, liver, and heart transplantation. Transplant Int 17 (2004) 109-119
38. Fernandez-Miranda C., de la Calle A., Morales J.M., et al. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients. a comparative study. Clin Transplant 12 (1998) 136-141
39. Wheeler D.C., Morgan R., Thomas D.M., et al. Factors influencing plasma lipid profiles including lipoprotein (a) concentration in renal transplant recipients. Transplant Int 9 (1996) 221-226
40. Olyaei A.J., Demattos A.M., and Bennett W.M. Cardiovascular complications of immunosuppressive agents in renal transplant recipients. Exp Opin Drug Saf 4 (2005) 29-44
41. National Kidney Foundation. K/DOQI clinical practice guidelines on managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 41 Suppl 3 (2003) S1-S92
42. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant 23 5 Suppl (2004) S194-S201
43. Wilkinson A., Davidson J., Dotta F., et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 19 (2005) 291-298
44. Ramos-Cebrian M., Torregnosa J.V., Guttierrez-Daman A., et al. Conversion from tacrolimus to cyclosporine could improve control of postransplant diabetes mellitus after renal transplantation. Transplant Proc 39 (2007) 2251-2253
45. Salifu M.O., Tedia F., Murty P.V., et al. Challenges in the diagnosis and management of new-onset diabetes after transplantation. Curr Diab Rep 5 (2005) 194-199
46. Pham P.T., Pham P.C., Lipshutz G.S., et al. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 36 (2007) 873-890
47. Steurer W., Malaise J., Mark W., et al. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols. Nephrol Dial Transplant 20 Suppl (2005) 1154-1162
48. Shaprio A.M., Ricordi C., Hering B.K., et al. International trial of the Edmonton Protocol for islet cell transplantation. N Engl J Med 355 (2006) 1318-1330
49. Morales J.M. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int Suppl 82 (2002) S81-S87
50. Koomans H.A., and Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 72 6 Suppl (2002) S9-S12
51. Eisen H., and Ross H. Optimizing the immunosuppressive regimen in heart transplantation. J Heart Lung Transplant 23 5 Suppl (2004) S207-S213
52. Dulcoux D., Motte G., Kribs M., et al. Hypertension in renal transplants: donor and recipient risk factors. Clin Nephrol 57 (2002) 409-413
53. O'Connor D., Barg A.P., Amend W., et al. Urinary kallikrein excretion after renal transplantation: relationship to hypertension, graft source and renal function. Am J Med 73 (1982) 475-481
54. Baran D.A., Galin I.D., and Gass A.L. Calcnieurin inhibitor-associated early renal insufficiency in cardiac transplant patients: risk factors and strategies for prevention and treatment. Am J Cardiovasc Drugs 4 (2004) 21-29
55. Gruber S.A., Pescowitz M.D., Simmons R.L., et al. Thromboembolic complications in renal allograft recipients. Transplantation 44 (1987) 775-778
56. Sezer S., Ozdemir F.N., Afsar B., et al. Subjective global assessment is a useful method to detect malnutrition in renal transplant patients. Transplant Proc 38 (2002) 517-520
57. Hussaini S.H., Oldroyd B., Stewart S.P., et al. Effects of orthotopic liver transplantation on body composition. Liver 18 (1998) 173-179
58. Pelletier S.J., Marasschio M.A., Schaubel D.E., et al. Survival benefit of kidney and liver transplantation for obese patients on the waiting list. Clin Transplant (2003) 77-88
59. Grady K.L., White-Williams C., Naftel D., et al. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multiinstitutional study of preoperative weight-height indices. Cardiac Transplant Research Database Group. J Heart Lung Transplant 18 (1999) 750-763
60. Whittier F.C., Evans D.H., Dutton S., et al. Nutrition in renal transplantation. Am J Kidney Dis 6 (1985) 405-411
61. Bellinguieri G, Bernardi A, et al: Metabolic syndrome after kidney transplantation. (in press)
62. Guida B., Trio R., Laccetti R., et al. Role of dietary intervention on metabolic abnormalities and nutritional status after renal transplantation. Nephrol Dial Transplant 22 (2007) 3304-3310
63. Miller D.G., Levine S.E., D'Elia J.A., et al. Nutritional status of diabetic and nondiabetic patients after renal transplantation. Am J Clin Nutr 44 (1986) 66-69
64. Worthington J.E., Martin S., Al-Hussein D.M., et al. Post-transplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 75 (2003) 1034-1040
65. Marcen R., Pascual J., Jl T., et al. Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major cause of late graft loss?. Transplantation 72 (2001) 57-62
66. Koote A.M.M., T'Hart-Erdman M., and Paul L.C. Dietary protein manipulation on cyclosporine therapy in chronic allograft rejection. Clin Transplant 2 (1988) 152-159
67. Feehally J., Bennett S.E., Harris K.P., et al. Is chronic allograft rejection a non-immunologic phenomenon?. Lancet 2 (1986) 486-488
68. Coffman T.M., Carr D.R., Yarger W.E., et al. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 43 (1987) 282-285
69. Badalamenti S., Salerno F., Lornezano E., et al. Renal effects of dietary supplementation with fish oil in cyclosporinetreated liver transplant recipients. Hepatology 22 (1995) 1695-1701
70. Weir M.R., klassen D.K., and Burdick J.F. A pilot study to assess the ability of an orally available selective thromboxane synthase inhibitor to improve renal function I cyclosporine-treated renal transplant recipients. J Am Soc Nephrol 2 (1992) 1285-1290
71. Berthoux F.C., Guerin C., Burgard G., et al. One-year randomized controlled trial with omega-3-fatty acid fish oil in clinical renal transplantation. Transplant Proc 24 (1992) 2578-2582
72. Perico N., Pasini M., Gaspari F., et al. Co-participation of thromboxane A2and leukotriene C4 and D4 in mediating cyclosporine-induced acute renal failure. Transplantation 52 (1991) 873-878
73. Hruska K.A., and Teitelbaum S.L. Renal osteodystrophy. N Engl J Med 133 (1995) 166-173
74. O'Shaunessy E.A., Dahl D.C., Smith C.L., et al. Risk factors for fractures in kidney transplantation. Transplantation 74 (2002) 362-366
75. Lane N.E., Sanchez S., Modin G.W., et al. Bone mass continues to decrease at the hip in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Mineral Res 15 (2000) 944-951
76. Lehman G., Ott U., Stein G., et al. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc 39 (2007) 3153-3158
77. Fan S.L.S., Almond M.K., Ball E., et al. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57 (2000) 684-689
78. Shane E., Addesso V., Namerow P.B., et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350 (2004) 767-776
79. Compston J.E. Osteoporosis after liver transplantation. Liver Transplant 9 (2003) 321-330
80. Monegal A., Navasa M., Guanahans N., et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine. A. Calcif Tissue Int 68 (2001) 83-86
81. Gianni S., Dangel A., Carrao G., et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Mineral Res 16 (2001) 2111-2117
82. Fine R., et al. Growth post-renal transplantation in children: lessons from pediatric transplants. Report of the NAPRTCS (1997) 85-89
83. Tonshoff B., et al. Growth in children after renal transplantation. Brit J Clin Practice 85 Suppl (1996) 34-37
84. Feldt-Rasmussen B., Lange M., Sulowicz W., et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 18 (2007) 2161-2171
85. Iglesia P., Diez J.J., Fernandez-reyes M.J., et al. Growth hormone, IGF-1 and its binding proteins (IGFBP-1 and -3) in adult uremic patients undergoing peritoneal and hemodialysis. Clin Endocrinol (Oxf) 60 (2004) 741-749
86. Sakamoto K., Yamada K., Arita S., et al. Sodium-losing nephrolopathy and distal tubular damage of transplant kidneys with FK-506 administration. Transplant Proc 27 (1995) 826-828
87. Ambuhl P.M. Posttransplant metabolic acidosis: a neglected factor in renal transplantation. Curr Opin Nephrol Hypertens 16 (2007) 379-387
88. Furth S.L., Casey J.C., Pyzik P.L., et al. Risk factors for urolithiasis in children on the ketogenic diet. Pediatric Nephrol 15 (2000) 125-128
89. Stapenhorst L., Sassen R., Beck B., et al. Hypocitraturia as a risk factor for nephrolcalcinosis after kidney transplantation. Pediatric Nephrol 20 (2005) 652-656
90. Melnick J.Z., Preisig P.A., Haynes S., et al. Converting enzyme inhibition causes hypocitraturia independent of acidosis or hypokalemia. Kidney Int 54 (1998) 1670-1674
91. Encinas J.L., Luis A., Avila L.F., et al. Nutritional status after intestinal transplantation in children. Eur J Pediatr Surg 16 (2006) 403-406
92. Sun C., Ward H.J., Paul W., et al. Profile of erythropoietin following renal transplantation: a recombinant human erythropoietin-based radioimmunoassay study. N Engl J Med 320 (1989) 151-157
93. McPartlend K.J., and Pompocelli J.J. Update on immunosuppressive drugs used in solid organ transplants and their nutritional implication. Nutr Clin Pract 22 (2007) 467-473
94. Kyle U.G., Nicod L., Romand J.A., et al. Four-year follow-up of body composition in lung transplant recipients. Transplantation 75 (2003) 821-828
95. Smits J.M., Vanhaecke J., Haverich A., et al. Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant. Clin Transplant (2003) 89-100 1997-1999